bluuebunny/crossref_metadata_2025_split huggingface dataset:
962-P: Assessment of Hybrid Closed-Loop Impact upon Glycemic Control, Weight, and Retinopathy
Authors: GIBB FRASER W. , FORBES SHAREEN , DOVER ANNA R. , STIMSON ROLAND H. , LYALL MARCUS 
Published: June 2024

Background: We sought to assess real-world outcomes in adults with type 1 diabetes commenced on hybrid closed loop (HCL).
Methods: Observational study of 254 adults following conversion from CSII to HCL in a secondary care setting. Outcomes included change in CGM metrics, HbA1c, weight and eye disease.
Results: Mean age was 41±14 years (70% female) and diabetes duration was 22±12 years. 102 were on Tandem CIQ, 79 on Medtronic 780G, 57 on Omnipod 5 and 16 on CAM APS. HbA1c fell by 0.64% (p &lt;0.001, mean follow up 467 days). Where HbA1c &gt;7.5% at baseline, the fall in HbA1c was 0.91% (p &lt;0.001). HbA1c &lt;7.5% increased from 39% to 65% and HbA1c &gt;9% decreased from 12% to 5% (p &lt;0.001). CGM metrics are presented below. There was no significant change in weight (+0.1 kg, p = 0.610) over a mean follow up of 356 days. Those with a &gt;5% improvement in TIR experienced greater weight gain (+0.6kg vs -1.2kg, p = 0.012). Of 113 individuals with routine retinal screening data, only 17 experienced any degree of worsening and this was not associated with change in TIR or HbA1c (but was associated with low baseline TIR [p = 0.03]). In a logistic regression model, lower age and higher HbA1c were associated with superior TIR response to HCL (but gender, BMI and socioeconomic deprivation were not).
Conclusion: HCL is associated with substantial glycemic benefits - particularly in those with highest baseline HbA1c. The extent of weight gain and EWDR appears to be small.

Disclosure
F.W. Gibb: Speaker's Bureau; Abbott. Advisory Panel; Insulet Corporation. Speaker's Bureau; Novo Nordisk. S. Forbes: None. A.R. Dover: None. R.H. Stimson: None. M. Lyall: None.
97-OR: Preclinical Characterization of MTX-101, a Novel KIRxCD8 Targeting Bispecific CD8 Treg Modulator
Authors: PATTON DANIEL , PHAM MINH , GARDELL JENNIFER L. , BOSTER DANIEL , JULIEN SUSAN , MCMAHAN CATHERINE , CRANE COURTNEY , SWIDEREK KRISTINE M. 
Published: June 2024

Introduction and Objectives: In healthy individuals, activation and expansion of CD8 regulatory T cells (CD8 Treg) leads to selective killing of pathogenic CD4 T cells without broad immunosuppression. In patients with autoimmunity, CD8 Treg appear dysfunctional, allowing pathogenic CD4 T cell expansion and downstream inflammatory events, causing damage to healthy tissues. MTX-101 is a bispecific CD8 Treg modulator targeting CD8 and KIR2DL(1/2/3), co-expressed on CD8 Treg. MTX-101 targets CD8 Treg to restore their function and reduce inflammation without unwanted immune cell activation or global immune suppression. By targeting a root cause of CD4-driven autoimmune diseases, our data suggest that MTX-101 is a promising CD8 Treg-specific therapeutic to restore immune balance for the treatment of Type 1 Diabetes (T1D).
Methods: We evaluated MTX-101 binding, mechanism of action, and specificity in vitro using human PBMCs and in vivo using a human CD4 T cell-driven GVHD model. Pharmacology and early tolerability were evaluated in humanized CD34+-engrafted NSG(IL-15Tg) mice.
Results: MTX-101 increased the activation and functions of CD8 Treg without activating other immune cells or affecting global immune responses in vitro, and improved outcomes in the acute GVHD model. In Balb/c and humanized mice, MTX-101 pharmacokinetics were consistent with antibody-like molecules. In humanized mice, MTX-101 bound CD8 Treg in peripheral blood and terminal tissues, with no resulting activation of immune cells. No induction of proinflammatory serum cytokines were observed following MTX-101 dosing at concentrations up to 50 mg/kg.
Conclusion: MTX-101 restores CD8 Treg functions and may provide durable resistance to autoimmune disease progression.

Disclosure
D. Patton: None. M. Pham: None. J.L. Gardell: Employee; Mozart Therapeutics. D. Boster: Employee; Mozart Therapeutics. S. Julien: Employee; Mozart Therapeutics. C. McMahan: None. C. Crane: Employee; Mozart Therapeutics. K.M. Swiderek: None.

Funding
Mozart Therapeutics
984-P: Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre System Initiation in People with Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy in France
Authors: GUERCI BRUNO , LEVRAT-GUILLEN FLEUR , DETOURNAY BRUNO , VICAUT ERIC , DEPOUVOURVILLE GERARD , EMERY CORINNE , RIVELINE JEAN-PIERRE 
Published: June 2024

Introduction: People with T2D treated with oral insulin-secretagogues are at risk for acute diabetes events (ADEs), including DKA and hypoglycemia. This study investigates the change in hospitalization rates for ADEs following initiation of FreeStyle Libre® system (FSL), in people with T2D in France, treated with oral insulin-secretagogue drugs without insulin.
Methods: Retrospective study of the French national SNDS claims database identified people with T2D treated with insulin-secretagogues without insulin and a FSL initiation date between 01/Aug/2017 to 31/Dec/2018. Data for the 12 months before and after FSL initiation were included. Hospitalizations were identified using ICD-10 codes for: DKA; hyperglycemia; hypoglycemic events; comas.
Results: 4,962 people with T2D on oral insulin-secretagogue drugs initiated FSL during the selection period. Of these, 8.7% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 2.4% in the year after initiation (Fig 1), a reduction of 72%. The reduction in ADEs was driven by -81% fewer admissions for DKA or hyperglycemia.
Conclusions: This study suggests that use of the FSL system is associated with reduced hospital admissions for ADEs in people with T2D in France, treated with oral insulin-secretagogue drugs without insulin.

Disclosure
B. Guerci: Advisory Panel; Abbott Diagnostics, Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Bayer Inc., Medtronic, Insulet Corporation, Dexcom, Inc., Boehringer-Ingelheim. F. Levrat-Guillen: Employee; Abbott. B. Detournay: Advisory Panel; AstraZeneca. Consultant; Abbott, AstraZeneca, Novo Nordisk, Sanofi, CEMKA, CERBA expert. E. Vicaut: Consultant; Abbott, Boston Scientific Corporation, COLOPLAST. G. DePouvourville: Advisory Panel; Abbott, Alexion Pharmaceuticals, Inc., AstraZeneca, Astellas Pharma Inc., Bayer Inc., Boehringer-Ingelheim, Bristol-Myers Squibb Company, Biogen. Research Support; GlaxoSmithKline plc. Advisory Panel; IQVIA Inc., Lundbeck, Janssen Pharmaceuticals, Inc., Moderna, Inc., Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company Limited, Viatris Inc., Edwards Life Sciences, UCB, Alexion Pharmaceuticals, Inc., DBV-Technology, EFPIA. C. Emery: None. J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca.

Funding
Abbott
989-P: The Effect of Continuous Glucose Monitoring on Postoperative Glucose Control in People with Type 2 Diabetes Mellitus Undergoing Coronary Artery Bypass Grafting—A Randomized Clinical Trial
Authors: SON HEEJUN , HO SOHN SUK , AH KIM HYUN , JEE CHOE HUN , LEE HYUNSUK , SEUNG JUNG HYE , MIN CHO YOUNG , SOO PARK KYONG , YOUNG HWANG HO , HEON KWAK SOO 
Published: June 2024

Introduction & Objective: Effective glycemic control following cardiac surgery improves overall clinical outcomes, and continuous glucose monitoring (CGM) is a valuable tool in achieving this objective. We investigated the effect of CGM on postoperative glycemic control in patients with diabetes after coronary artery bypass grafting (CABG).
Method: In this randomized clinical trial involving adults with type 2 diabetes undergoing CABG, all participants utilized real-time CGM (Dexcom G6) after scheduled CABG, and received a basal bolus insulin regimen. The subjects were randomly assigned to either a test group utilizing CGM for glycemic control, or a control group with blinded CGM measures, relying on point-of-care measures. The primary outcome was the percentage of time in range (TIR) of blood glucose between 70-180 mg/dL, as measured by CGM.
Results: Of total 96 subjects, 49 were in the test group and 47 in the control group. CGM was applied for 5.9 ± 2.0 days. Participants had a mean age of 68.9 ± 9.3 years, and baseline glycated hemoglobin was 7.2 ± 0.9 %. The least squares (LS) mean ± standard error of TIR was 58.9 ± 2.7%, 50.2 ± 2.8% in the test and control group, respectively. TIR was significantly higher in the test group than in the control group when adjusted with age, sex, body mass index, and baseline glycated hemoglobin (LS mean difference, 8.3%; 95% confidence interval, 0.4-16.3; p=0.041). Time above range and mean glucose levels were also significantly lower in the test group than in the control group. No differences in time below range, coefficient of variation, and hypoglycemic event rate were observed between the two groups.
Conclusion: In this randomized clinical trial, Dexcom G6 CGM has enhanced glycemic control without increasing the risk of hypoglycemia. Given the benefits of effective glycemic control on perioperative outcomes, CGM may be helpful in managing type 2 diabetes after CABG.

Disclosure
H. Son: None. S. Sohn: None. H. Kim: None. H. Choe: None. H. Lee: None. H. Jung: Research Support; Novo Nordisk. Y. Cho: None. K. Park: None. H. Hwang: None. S. Kwak: Employee; SNUH Venture.
99-OR: SLC7A2-Dependent Arginine Transport in α-Cells Signals Arginine tone to Regulate Insulin Secretion
Authors: STANLEY JADE , DEAN DANIELLE , SELLICK KATELYN 
Published: June 2024

Diabetes results from a decline in pancreatic β-cell function with simultaneous hyperglucagonemia, resulting in hyperglycemia. Over 60 years ago, arginine was identified as a potent secretagogue of glucagon secretion, yet the mechanisms behind this are not thoroughly elucidated. Recently, we found that the cationic amino acid transporter, SLC7A2/CAT2 is the most highly expressed amino acid transporter in human pancreatic α-cells and three-fold higher in α-cells than it is in β-cells and other islet cell types in both mouse and human islets. We showed that global loss of SLC7A2 in mice resulted in impaired arginine stimulated glucagon and insulin secretion. However, based on the expression pattern of SLC7A2, we predicted β-cells might be poor arginine sensors. To assess the role of α-cell expression of SLC7A2 arginine-stimulated hormone secretion, we made either α-cell or β-cell specific Slc7a2-/- (α7A2KO;β7a2KO) mice. Hormone levels were measured in 6-hour fasted and arginine challenged mice (2g/kg via intraperitoneal injection). Blood glucose, glucagon, and insulin levels were not significantly different after fasting in α7A2KO, β7a2KO, and Slc7a2f/f cre- (7a2f/f) control mice. As expected, 15 minutes after arginine bolus, α7A2KO mice had significantly lower arginine stimulated glucagon levels compared to β7a2KO and 7a2f/f mice (arginine-stimulated glucagon - β7a2KO 102.4 ± 36.8 pM vs. α7A2KO 14.1 ± 18.7 pM vs. 7a2f/f 103.8 ± 76.5; n=6-11 p&lt;0.001). However surprisingly, β7a2KO mice had similar insulin levels to control mice, while α-cell specific α7A2KO mice had a two fold reduction in arginine stimulated insulin secretion (arginine-stimulated insulin - β7a2KO 424.1 ± 172.3 pM vs. α7A2KO 158.1 ± 57.5 pM vs. 7a2f/f 368.2 ± 212.4; n=6-11 p&lt;0.001). In summary, we found that α-cells act as the predominant arginine sensor in islets communicating arginine tone to neighboring β-cells perhaps through proglucagon-derived peptides or other α-cell products.

Disclosure
J. Stanley: None. D. Dean: None. K. Sellick: None.

Funding
National Institutes of Health (R01DK132669, R01DK130296, F31DK134158, and P30DK020593)
990-P: Developing a Breath-Based Glucose Estimation Device for People with Type 2 Diabetes
Authors: GOURDY PIERRE , CAZALS LAURENT , FRANÇOIS-MARSAL CLARISSE , BLANC CALVO SOPHIE , ISZ SANDRINE , LEPAGE BENOÎT , FLACKE FRANK 
Published: June 2024

Introduction and Objectives: BOYDSense is developing a breath-based monitoring system for chronic conditions starting with glucose monitoring for people with type 2 diabetes (T2D). These are results of a proof-of-concept study to evaluate the correlation of Volatile Organic Compounds (VOCs) in exhaled human breath with SMBG glucose values. The aim of this study, performed at CHU-Toulouse, was to develop a first glucose estimation algorithm for the BOYDSense breath-based technology and to assess its performance.
Methods: The study combined 2 successive phases and enrolled in total 130 subjects with T2D on OAD and/or GLP-1 and/or basal insulin. In phase 1 100 subjects underwent a standardized meal challenge and, at each sampling point, a reference glucose value (venous blood) and 3 breath data-sets were collected to train the algorithm supported by AI. In phase 2 the developed algorithm was used to display glucose estimates. 30 subjects underwent the same procedure as described above and also SMBG readings were taken at the sampling points. The study center collected the data and conducted the data analysis.
Results: In phase 2, 630 data-pairs (breath/SMBG) were collected. For the complete dataset, a Consensus Error-Grid-Analysis (C-EGA) for T2D was calculated. zone A contained 79.7% and zone A+B 99.7% of all readings. Only 2 readings were in zone C. A comparison of the C-EGA of the 3 breath strokes at each sampling point showed no obvious differences between the strokes (zone-A/zone-A+B): breath-1 80.0%/99.5%, breath-2 78.1%/100%, breath-3 81.0%/ 99.5% The overall MARD was estimated to 19.6%. The auto-sampling prototypes demonstrated a high reliability (99.9%).
Conclusion: The prospective performance of the first algorithm iteration of the BOYDSense breath analyzer showed in comparison to real-life SMBG readings very promising results towards a new glucose estimation system supporting people with T2D. The high reliability speaks to an already advanced stage of the hardware development.

Disclosure
P. Gourdy: Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Research Support; Novo Nordisk A/S. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Advisory Panel; Pfizer Inc., Bayer Inc. Research Support; BoydSense. Speaker's Bureau; Amarin Corporation, AbbVie Inc., Boehringer-Ingelheim. Advisory Panel; Boehringer-Ingelheim, AstraZeneca. L. Cazals: None. C. François-Marsal: None. S. Blanc Calvo: None. S. Isz: None. B. Lepage: None. F. Flacke: Consultant; BOYDSense SAS, Sinocare Meditech Inc., embecta.
994-P: Real-World Evaluation of the Implantable 180-Day Eversense E3 CGM System
Authors: TWEDEN KATHERINE S. , ROMAROWSKI BEN , MDINGI COLLEEN , KAUFMAN FRANCINE R. 
Published: June 2024

Background: The 180-day implantable Eversense E3 CGM System was commercialized in 2022 for adults with diabetes. This is the first real-world assessment of the 180-day E3 System in patients using open-loop insulin regimens.
Methods: Sensor glucose (SG) data obtained from the Eversense Data Managment System (DMS) for the first 1000 users in the US were used to evaluate CGM metrics. Twenty-four-hour transmitter wear time, mean SG and glycemic variability metrics, glucose management indicator (GMI), and percent in glycemic ranges were calculated over 180 days. Age, type of diabetes and gender were self-reported.
Results: The first 1000 real-world E3 CGM Systems were inserted in users of mean age 50 yrs., 57.5% male, 40.6% T1D, 28.2% T2D and 31.2% not reported. DMS provided mean 41,584±9309 CGM readings over 180 days per user. Mean values of the CGM metrics were 160.6 mg/dL for SG, 52.9 mg/dL for SD, 0.33 for CV, and 7.15% for GMI (Table). The %SG in the various glycemic ranges was as follows: 0.94% (&lt;54 mg/dL), 3.3% (&lt;70 mg/dL), 64.6% (≥70 to 180 mg/dL), 32.1% (&gt;180 mg/dL) and 9.9% (&gt;250 mg/dL). Median transmitter wear time was 83.0%. Percent of users achieving recommended glucose goals was promising with at least 70% achieving hypoglycemia targets.
Conclusion: This real-world evaluation of the Eversense E3 CGM System used with open-loop insulin regimens demonstrated that Eversense assists patients in effectively managing diabetes.

Disclosure
K.S. Tweden: Employee; Senseonics Inc. B. Romarowski: Employee; Senseonics Inc. C. Mdingi: Employee; Senseonics. F.R. Kaufman: Employee; Senseonics. Consultant; Twin Health.
Struktur Komunitas Satuan Lanskap di Lereng Gunung Slamet Jawa Tengah
Authors: Fikriyya Nabela , Silalahi Marina , Zukarnaen Rizmoon Nurul , Nisyawati Nisyawati , Helmanto Hendra , Putri Adinda Kurnia 
Published: June 2024

Masyarakat Lereng Gunung Slamet memiliki pengetahuan diversifikasi satuan lanskap yang didasarkan atas fungsi, karakteristik, dan kepemilikan. Tujuan penelitian ini adalah untuk mempelajari struktur komunitas satuan lanskap yang dimanfaatkan oleh Masyarakat Lereng Gunung Slamet. Penelitian dilakukan pada bulan Juli 2019 — Januari 2020 di desa Lereng Gunung Slamet yaitu, (1) Desa Ragatunjung, (2) Desa Cipetung, dan (3) Desa Pandansari Kecamatan Paguyangan, Kabupaten Brebes. Pengumpulan data botani dilakukan dilakukan secara purposive sampling menggunakan transek kuadrat. Analisis vegetasi diolah menggunakan Indeks Nilai Penting (INP), Indeks Keanekaragaman (H’), Indeks Kekayaan (DMg), Indeks Kemerataan (e’), dan Indeks Kesamaan komunitas. Berdasarkan Analisis vegetasi ditemukan 136 spesies yang dikategorikan ke dalam 11 genus dan 55 famili. Analisis struktur komunitas dapat dilihat pada H’ berkisar antara 1,57—28,9 yang termasuk dalam kategori sedang. DMg berkisar antara 11,82 – 28,8 dan Indeks kemerataan berkisar antara 0,11—0,92. Indeks kesamaan antar satuan lanskap, wanah dan majegan merupakan yang tertinggi yakni 62,67% yang termasuk kategori tinggi. Selanjutnya nilai Indeks kesamaan jenis lanskap yang sama antar desa, tertinggi pada lanskap majegan di Desa Cipetung dan Pandansari (45,71%.) dan wanah pada Desa Ragatunjung dan Desa Cipetung (42,86 %).
Класифікація неізоморфних груп деякого класу черніковських 3-груп
Authors: Порохнавець І. М. , Шапочка І. В. 
Published: June 2024

В цiй роботi описуються з точнiстю до iзоморфiзму деякi чернiкоськi 3-групи, що є
циклiчними розширеннями повних абелевих 3-груп з умовою мiнiмальностi.
Нехай ℂ3∞ — адитивна квазiциклiчна 3-група, а ℂn3∞ — зовнiшня пряма сума n екземплярiв
квазiциклiчної 3-групи ℂ3∞ для деякого натурального числа n. Добре вiдомо, що група Aut
ℂn3∞ iзоморфна повнiй лiнiйнiй групi GL(n, ℤ3), де ℤ3 — кiльце цiлих 3-адичних чисел.
Тому надалi для довiльної матрицi A ∈ GL(n, ℤ3) та довiльного елемента c ∈ ℂn3∞ через
A(c) позначатимемо образ елемента c при автоморфiзмi, що вiдповiдає матрицi A. Нехай {ar
| r ∈ ℕ0} — множина всiх твiрних елементiв групи ℂn3∞, де ℕ0 = ℕ ∪ {0}, причому 3a0 = 0,
3ar = ar-1 для довiльного r ∈ ℕ.
Розглянемо циклiчну адитивну групу H порядку 27 з твiрним елементом h i деяке матричне
зображення Γ цiєї групи степеня n над кiльцем ℤ3. Образ будь-якого елемента h' групи H
позначатимемо через Γh'. Визначимо дiю · групи H на групi ℂn3∞ за правилом h' · c = Γh'
(c) для довiльних елементiв h' ∈ H i c ∈ ℂn3∞. Пiдкре-слимо, що ядро Ker Γ є пiдгрупою
стабiлiзатора кожного елемента iз ℂn3∞. Нескладно переконатися, що множина
A(ℂn3∞, H, Γ) = {c ∈ ℂn3∞ | h · c = c}
є пiдгрупою групи ℂn3∞. Для матричного зображення Γ групи H та деякого елемента c ∈
A(ℂn3∞, H, Γ) побудуємо групу G(Γ, c) наступним чином:
G(Γ, c) = H × ℂn3∞,
а бiнарна операцiя + задається так
(ih, c1) + (jh, c2) = ((i + j)h, μi,j + jh · c1 + c2),
де i, j ∈ {0, 1, . . . , 26}, c1, c2 ∈ ℂn3∞,

Вiдомо, що таким чином побудована група є циклiчним розширенням групи ℂn3∞ за допомогою
групи H, а як наслiдок, є чернiковською 3-групою.
В роботi описанi з точнiстю до iзоморфiзму всi чернiковськi 3-групи, фактор-група яких
за максимальною повною абелевою пiдгрупою є циклiчною групою порядку 27 i якi
визначаються матричним ℤ3-зображенням [3]

де ῆ — незвiдна ℤ3-матриця 18-го порядку вигляду
“Sabor de Química”, de Roniwalter Jatobá, e “Dente de Ouro”, de Rubens Figueiredo
Authors: Silva Rafael Lucas Santos da 
Published: June 2024

Roniwalter Jatobá e Rubens Figueiredo são escritores muito distintos em termos estéticos e temáticos, porém percebemos que surge uma semelhança, específica entre duas narrativas, acerca da configuração da representação dos efeitos causados pelo movimento migratório na vida de dois protagonistas. Em virtude dessa identificação, o presente ensaio tem como objetivo criar uma leitura comparativa entre as narrativas “Sabor de química” (1976), de Roniwalter Jatobá, e “Dente de ouro” (2006), de Rubens Figueiredo, tendo o Materialismo Lacaniano como ancoragem teórico-crítica. As experiências ficcionais dos protagonistas das narrativas revelam experiências de migração marcadas por sofrimento, desamparo e precariedade, a partir das quais buscamos evidenciar que estes contos possuem em comum um universo imaginário orgânico, com visões de mundo que apontam para horizontes análogos, cuja ressonância intertextual forma um esquema estético reflexivo sobre a dimensão simbólica e subjetiva do processo de modernização autoritário e desigual da sociedade brasileira.
Palavras-chave: Literatura Brasileira contemporânea; Materialismo Lacaniano; Trabalho; Os pobres na literatura.
Efeito hipolipemiante da farinha de feijão branco (Phaseolus vulgaris) em camundongos hiperlipidêmicos
Authors: Molz Simone , Cordeiro Debora Nack 
Published: June 2024

Neste estudo, avaliou-se o efeito hipolipemiante de uma preparação caseira de farinha de feijão branco (Phaseolus vulgaris) em camundongos hiperlipidêmicos. Os animais controles receberam água ou doses crescentes (0,5; 0,75 e 1,0 g/kg) da farinha de feijão branco pela via oral (v.o.) 1 hora antes da administração de solução salina por via intraperitoneal (i.p.). Os animais hiperlipidêmicos receberam água ou farinha de feijão branco (0,5; 0,75 e 1,0 g/kg) v.o. e posteriormente Triton WR-1339 (200 mg/kg) pela via i.p. Vinte e quatro horas após a aplicação de salina ou Triton WR-1339, foi realizada a coleta sanguínea para dosagem de colesterol total (CT) e triglicerídeos (TG). Os resultados foram analisados pela análise de variância de uma via, seguido do teste de Tukey e considerados significativos quando p<0,05. A administração de concentrações crescentes (0,5; 0,75 e 1,0 g/kg) da farinha de feijão branco aos animais controles não alterou a concentração de TG ou CT, evidenciando que a farinha de feijão branco não tem efeito per se sob a concentração dos lipídeos plasmáticos. Entretanto, a farinha de feijão branco na dose de 1,0 g/kg diminuiu significativamente o aumento de CT e TG (p<0,05 e 0,001, respectivamente) e na dose de 0,75 g/kg diminuiu a elevação de CT causada pelo Triton WR-1339 (p< 0,001). Conclui-se que o consumo de uma preparação caseira de farinha de feijão branco possui efeito hipolipemiante estatisticamente significativo na redução da concentração de TG e CT no modelo experimental de hiperlipidemia induzido pelo Triton WR-1339 em camundongos.